The Human Phenomenon

The Human Phenomenon
The Human Phenomenon

Mobile Touchpoints

72% of physicians now own a tablet device, up from 66% in 2012‡

53% of healthcare marketing directors invested in mobile/tablet apps this year, up from 35% in 2012**

8-12% increase in key performance indicators when an iPad is used in a call††

7 in 10 physicians have at least one patient who shares health measurement with them‡

83% of healthcare marketing directors with a consumer mobile budget reported an increase in spending in 2013 **

90% reduction in the proportion of short calls (of less than 2 minutes) when an iPad is used††

70% of the sales calls made by reps who possess an iPad do not incorporate the device††

55% of pharma brand information and services obtained by ePharma physicians is sourced online. Physicians expressed a desire to increase this to 65%†

†Source: Manhattan Research, ePharma Physician 2012
‡ Source: Manhattan Research, Taking the Pulse 2013
**Source: MM&M/Ogilvy CommonHealth Healthcare Marketers Trend Report 2013
††MD Mindset: Use of iPads by Pharmaceutical Sales Profession

TO SEE STATS ON US SMARTPHONE AND TABLE ADOPTION, CLICK HERE

Next: 10 Apps with Aptitude

Page 2 of 3
You must be a registered member of MMM to post a comment.
close

Next Article in Directories

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.